This represents an immediate increase in net tangible book value of $1.27 per share to our existing shareholders....
... all of which warrants were exercised on May 1, 2013,...
...We intend to use the net proceeds from this offering to fund further clinical development of ARIKACE for Pseudomonas in CF and for NTM, to fund our efforts to obtain regulatory approvals and commercialize ARIKACE for Pseudomonas in CF and for NTM, to invest in increased third-party manufacturing capacity in anticipation of possible commercial launch of ARIKACE in Europe and the United States, and the balance to fund working capital, capital expenditures, general research and development, and other general corporate purposes, which may include the acquisition or in-license of additional compounds, product candidates, technology or businesses.....
10.81 is a bargain so if the shorts are going to play games lower, I am more than willing to accommodate them. The bottom has now been written in stone and anything lower makes it Christmas in July. Consider the premarket a gift from the shorts. These cheap shares will not last long. It is every man for himself now,
Leaving London this morning..read this with breakfast...overall I believe this to be positive..The
wording either needed to be a little more closely thought out, or it was..The part where Lewis said
"Anticipation of possible commercialization in the US, and in Europe" is a little of a snitch. I would
have said" Anticipation of commercialization..." Makes one wonder if they know they're going to
get bought out...or sell the rights, and continue to build this into a completely different company.
As he states, they can use the funds for the purchase of other indications, and offerings..This guy
sure has some really big ideas...Off we go.
Maybe they don't need the money now, or maybe they should have waited until possibly the SP was higher at year end. Maybe they are going to partner with some entity and needed funds for cocktail drug with Arikace or even Iplex to further the development process. I don't think Lewis intends for Insmed to be a one trick pony.